Surging demand for Korean pharma in 2023 ahead of CPHI Korea
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Subscribe To Our Newsletter & Stay Updated